Pack Type Definition

Created by Maximilian Rupp, last modified on Apr 28, 2020

Ideation Background

The goal of this ideation exercise is to maintain pack types in an efficient and easy to use way.

> (i) **Early Draft**
> This is an early draft and outcome of our first round of internal ideation. Please keep in mind that the screens illustrate a study in a simplified way.

Potential Screenflow

1. Medication Pack Types - Section

## Ideation Background

The goal of this ideation exercise is to maintain pack types in an efficient and easy to use way.

Study 20000109

View Demand Plan ▾   ⤢

Study Header | IRT | Contacts | Countries | Medication Pack Types | Study Structure | Site Events

General Data

Study ID:	(Earliest) First Patient First Visit:
20000109	Oct 20, 2019
Study Description:	(Latest) Last Patient First Visit:
SAP TMC E2E 09	Apr 20, 2020
Study Type:	(Latest) Last Patient Last Visit:
Double-blind randomized	Apr 20, 2021
WBS:	Enrolment Curve:
123456789	Medium
Cost Center:	EudraCT:
300003821	2020-101010-02
Blinding Scenario:	External Distribution Network:
Pack type	☐
Therapeutic Area:	Distribution Network:
Oncology	Fisher
Study Status:	Central Packaging Location:
New	DE20
Study Phase:	Auto Demand:
II	☐
Clinical Version:	
1.0	

IRT

IRT Provider:	First Milestone Visit:
Catalent	2
IRT Trigger Visit:	Actual Start:
2	
Enrolment Threshold:	Automated Distribution:
20%	☑
Duration until Trigger Visit:	Customer Group:
	Oncology

Contacts

Contacts (5)   Add Delete   Search 🔍 ⚙

	User ID		Name	Role	Phone Number	Email Address	Messenger	Delegate	
☐	U3942	🗗	Tina Tafani	Clinical Trial Manager ⌄	+1-541-754-3010	tina.tafani@email.com	<Messenger URL>	Sam Tucker	🗗
☐	U2744	🗗	Susan Shen	Supply Chain Planner ⌄	+1-541-754-3008	susan.shen@email.com	<Messenger URL>	Elisabeth Leonard	🗗
☐	U3664	🗗	Daniel Denisson	Distribution Planner ⌄	+1-541-754-3006	daniel.denisson@email.com	<Messenger URL>	Robert Michaels	🗗
☐	U2449	🗗	Clark Clegg	Warehouse Clerk ⌄	+1-541-754-3004	clark.clegg@email.com	<Messenger URL>	Dana Parker	🗗
☐	U3127	🗗	Pablo Paolo Pereira	Production Manager ⌄	+1-541-754-3002	pablo.paolo.pereira@email.com	<Messenger URL>	Marcia Braziel	🗗

Countries

Depot Assignment:
- ⦿ Assignment at Country Level
- ○ Assignment at Country & Pack Type Level

Label Group Assignment:
- ⦿ Assignment at Country Level
- ○ Assignment at Country & Pack Type Level

Countries (5)   Add Delete Collapse All   Search 🔍 ⚙

		Country	Region	Depot	Label Group	Depot to Site Delivery Lead Time		Status	Regulatory Approval	FPFV	
☐	>	Australia 🗗	Pacific	40057349 🗗	M1 🗗	20	days	Active ⌄	✓	Oct 20, 2019 📅	Apr 2
☐	>	Canada 🗗	North America	40038643 🗗	M1 🗗	11	days	Inactive ⌄	✓	Oct 20, 2019 📅	Apr 2
☐	>	Germany 🗗	Europe	40011274 🗗	M1 🗗	8	days	Active ⌄	✓	Oct 20, 2019 📅	Apr 2
☐	>	France 🗗	Europe	40027673 🗗	M1 🗗	8	days	Active ⌄	✓	Oct 20, 2019 📅	Apr 2
☐	⌄	United States 🗗	North America	🗗	M1 🗗	9	days	Active ⌄	✓	Oct 20, 2019 📅	Apr 2
☐		East 🗗	North America	40090832 🗗	M1 🗗	13	days	Active ⌄	✓	Oct 20, 2019 📅	Apr 2
☐		West	North America	40012211 🗗	M1 🗗	9	days	Active ⌄	✓	Oct 20, 2019 📅	Apr 2
		Sum									

Medication Pack Types

Pack Type Definition | Material Assignment | Assignment Overview

Pack Types (3)   Add Delete   Search 🔍 ⚙

	Pack Type ID	Pack Type Description	Status
☐	KIT3	Active 200mg double blind	Active ⌄
☐	KIT2	Active 100mg double blind	Active ⌄
☐	KIT1	Active 0mg double blind	Active ⌄

Study Structure

Treatment Group Definition | Treatment Schedule | Treatment Assignment

Treatment Groups (4)   Copy Add Delete   Search 🔍 ⚙

	Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit
☐	TG04	Placebo (active 0mg double blind)	1				Day
☐	TG03	Low dosage (active 100mg double blind)	1				Day
☐	TG02	Medium dosage (active 200mg double blind)	1				Day
☐	TG01	High dosage (active 400mg double blind)	1	10%			Day

Site Events

Materials (15)   Add Date Add Delete   Search 🔍 ⚙

	Material ID		Material Description	Country		Apr 12, 2020	May 31, 2020
☐	1188	🗗	Active 0mg	Australia	🗗		
☐	1189	🗗	Active 100mg	Australia	🗗		15
☐	1190	🗗	Active 200mg	Australia	🗗		
☐	1191	🗗	Active 0mg	Canada	🗗	13	
☐	1192	🗗	Active 100mg	Canada	🗗		
☐	1193	🗗	Active 200mg	Canada	🗗		
☐	1188	🗗	Active 0mg	Germany	🗗		15
☐	1189	🗗	Active 100mg	Germany	🗗		
☐	1190	🗗	Active 200mg	Germany	🗗	13	
☐	1188	🗗	Active 0mg	France	🗗		
☐	1189	🗗	Active 100mg	France	🗗		
☐	1190	🗗	Active 200mg	France	🗗		15
☐	1191	🗗	Active 0mg	United States	🗗		
☐	1192	🗗	Active 100mg	United States	🗗	13	
☐	1193	🗗	Active 200mg	United States	🗗		

Draft saved   Save   Cancel

2. Material Assignment

Medication Pack Types

Pack Type Definition	Material Assignment	Assignment Overview

Countries (9) — Unassign

Country	Label Group	KIT1	KIT2	KIT3
Austria (AT)	L1			
Canada (CA)	L7			
Germany (DE)	L1			
France (FR)	L4			
United States (US)	L7			
India (IN)	L5			
Italy (IT)	L6			
Spain (ES)	L3			
Switzerland (CH)	L2			

Material Catalogue — Auto-Create Material Add Remove

Material ID	Material Icon	Name

KIT 1 Assign
KIT 2 Assign
KIT 3 Assign

Study Structure

Treatment Group Definition	Treatment Schedule	Treatment Assignment

Treatment Groups (4) — Copy Add Delete Search

Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit
TG04	Placebo (active 0mg double blind)	1				Day
TG03	Low dosage (active 100mg double blind)	1				Day
TG02	Medium dosage (active 200mg double blind)	1				Day
TG01	High dosage (active 400mg double blind)	1	10%			Day

Site Events

Draft saved Save Cancel

3. Material Assignment (Add to Catalogue)

Add to Catalogue

Material Name:

Placebo EU ✕ Active 100mg EU ✕ Active 200mg EU ✕ 3 More ⌄

Material ID	Icon	Name
345678901234504711		Placebo EU
345678901234504712		Active 100mg EU
345678901234504713		Active 200mg EU
345678901234505011		Placebo US
345678901234505012		Active 100mg US
345678901234505013		Active 200mg US

Save Cancel

4. Material Catalogue Updated

Material Catalogue (6) — Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711		Placebo EU
345678901234504712		Active 100mg EU
345678901234504713		Active 200mg EU
345678901234505011		Placebo US
345678901234505012		Active 100mg US
345678901234505013		Active 200mg US

Material catalogue has been updated

5. Countries Selected for Material Assignment

Countries (9) — Unassign

Country	Label Group	KIT1	KIT2	KIT3
☑ Austria (AT)	L1			
Canada (CA)	L7			
☑ Germany (DE)	L1			
France (FR)	L4			
United States (US)	L7			
India (IN)	L5			
Italy (IT)	L6			
Spain (ES)	L3			
Switzerland (CH)	L2			

6. Material Selected for Assignment

Medication Pack Types

Pack Type Definition | Material Assignment | Assignment Overview

Countries (9) Unassign 🔲 #

Country	Label Group	KIT1	KIT2	KIT3
☑ Austria (AT)	L1			
☐ Canada (CA)	L7			
☑ Germany (DE)	L1			
☐ France (FR)	L4			
☐ United States (US)	L7			
☐ India (IN)	L5			
☐ Italy (IT)	L6			
☐ Spain (ES)	L3			
☐ Switzerland (CH)	L2			

KIT 1
Assign

KIT 2
Assign

KIT 3
Assign

Material Catalogue (6) Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711	🟥	Placebo EU
345678901234504712	🟩	Active 100mg EU
345678901234504713	🟦	Active 200mg EU
345678901234505011	🟨	Placebo US
345678901234505012	🟪	Active 100mg US
345678901234505013	🟪	Active 200mg US

Study Structure

Treatment Group Definition | Treatment Schedule | Treatment Assignment

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

	Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit	
☐	TG04	Placebo (active 0mg double blind)	1				Day	
☐	TG03	Low dosage (active 100mg double blind)	1				Day	
☐	TG02	Medium dosage (active 200mg double blind)	1				Day	
☐	TG01	High dosage (active 400mg double blind)	1	10%			Day	

Site Events

Draft saved Save Cancel

7. Material Assignment Confirmation

Medication Pack Types

Pack Type Definition | Material Assignment | Assignment Overview

Countries (9) Unassign 🔲 #

Country	Label Group	KIT1	KIT2	KIT3
☑ Austria (AT)	L1			
☐ Canada (CA)	L7			
☑ Germany (DE)	L1			
☐ France (FR)	L4			
☐ United States (US)	L7			
☐ India (IN)	L5			
☐ Italy (IT)	L6			
☐ Spain (ES)	L3			
☐ Switzerland (CH)	L2			

KIT 1
Assign

KIT 2

Material Catalogue (6) Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711	🟥	Placebo EU
345678901234504712	🟩	Active 100mg EU
345678901234504713	🟦	Active 200mg EU
345678901234505012	🟪	Active 100mg US
345678901234505013	🟪	Active 200mg US

⊡ Assign

Assign material Placebo EU (345678901234504711) to selected countries?

Country	Label Group	Kit1	Kit 2	Kit3
Austria (AT)	L1	🟥		
Germany (DE)	L1	🟥		

Assign Cancel

Study Structure

Treatment Group Definition | Treatment Schedule | Treatment Assignment

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

	Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit	
☐	TG04	Placebo (active 0mg double blind)	1				Day	
☐	TG03	Low dosage (active 100mg double blind)	1				Day	
☐	TG02	Medium dosage (active 200mg double blind)	1				Day	
☐	TG01	High dosage (active 400mg double blind)	1	10%			Day	

Site Events

Draft saved Save Cancel

8. Material Assigned Successfully

Medication Pack Types

Pack Type Definition | Material Assignment | Assignment Overview

Countries (9) Unassign 🔲 #

Country	Label Group	KIT1	KIT2	KIT3
☐ Country				
☐ Austria (AT)	L1	🟥		
☐ Canada (CA)	L7			
☐ Germany (DE)	L1	🟥		
☐ France (FR)	L4			
☐ United States (US)	L7			
☐ India (IN)	L5			
☐ Italy (IT)	L6			
☐ Spain (ES)	L3			
☐ Switzerland (CH)	L2			

KIT 1
Assign

KIT 2
Assign

KIT 3
Assign

Material Catalogue (6) Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711	🟥	Placebo EU
345678901234504712	🟩	Active 100mg EU
345678901234504713	🟦	Active 200mg EU
345678901234505011	🟨	Placebo US
345678901234505012	🟪	Active 100mg US
345678901234505013	🟪	Active 200mg US

Study Structure

Treatment Group Definition | Treatment Schedule | Treatment Assignment

Materials have been added

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

	Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit	
☐	TG04	Placebo (active 0mg double blind)	1				Day	
☐	TG03	Low dosage (active 100mg double blind)	1				Day	
☐	TG02	Medium dosage (active 200mg double blind)	1				Day	
☐	TG01	High dosage (active 400mg double blind)	1	10%			Day	

Site Events

Draft saved Save Cancel

9. All Materials Assigned

Medication Pack Types

| Pack Type Definition | Material Assignment | Assignment Overview |

Countries (9) Unassign ⚏

Country	Label Group	KIT1	KIT2	KIT3
Austria (AT)	L1	🟥	🟩	🟦
Canada (CA)	L7			
Germany (DE)	L1	🟥	🟩	🟦
France (FR)	L4			
United States (US)	L7			
India (IN)	L5			
Italy (IT)	L6			
Spain (ES)	L3			
Switzerland (CH)	L2	🟨	🟪	🟪

KIT 1 Assign
KIT 2 Assign
KIT 3 Assign

Material Catalogue (6) Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711	🟥	Placebo EU
345678901234504712	🟩	Active 100mg EU
345678901234504713	🟦	Active 200mg EU
345678901234505011	🟨	Placebo US
345678901234505012	🟪	Active 100mg US
345678901234505013	🟪	Active 200mg US

Study Structure

| Treatment Group Definition | Treatment Schedule | Treatment Assignment |

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit
TG04	Placebo (active 0mg double blind)	1				Day
TG03	Low dosage (active 100mg double blind)	1				Day
TG02	Medium dosage (active 200mg double blind)	1				Day
TG01	High dosage (active 400mg double blind)	1	10%			Day

Site Events

Draft saved Save Cancel

---

10. Material Assignment (Austria (AT) KIT1 Popover)

Medication Pack Types

| Pack Type Definition | Material Assignment | Assignment Overview |

Countries (9) Unassign ⚏

Country	Label Group	KIT1	KIT2	KIT3
Austria (AT)	L1	🟥	🟩	🟦
Canada (CA)				
Germany (DE)				
France (FR)				
United States (US)				
India (IN)				
Italy (IT)				
Spain (ES)	L3			
Switzerland (CH)	L2	🟨	🟪	🟪

Austria (AT) KIT1 Details
Material ID:
345678901234504711
Material Name:
Placebo EU

KIT 1 Assign
KIT 2 Assign
KIT 3 Assign

Material Catalogue (6) Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711	🟥	Placebo EU
345678901234504712	🟩	Active 100mg EU
345678901234504713	🟦	Active 200mg EU
345678901234505011	🟨	Placebo US
345678901234505012	🟪	Active 100mg US
345678901234505013	🟪	Active 200mg US

Study Structure

| Treatment Group Definition | Treatment Schedule | Treatment Assignment |

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit
TG04	Placebo (active 0mg double blind)	1				Day
TG03	Low dosage (active 100mg double blind)	1				Day
TG02	Medium dosage (active 200mg double blind)	1				Day
TG01	High dosage (active 400mg double blind)	1	10%			Day

Site Events

Draft saved Save Cancel

---

11. Material Assignment (Number View)

Medication Pack Types

| Pack Type Definition | Material Assignment | Assignment Overview |

Countries (9) Unassign ⚏

Country	Label Group	KIT1		KIT2	
Austria (AT)	L1	🟥 345678901234504711		🟩 345678	
Canada (CA)	L7				
Germany (DE)	L1	🟥 345678901234504711		🟩 345678	
France (FR)	L4				
United States (US)	L7				
India (IN)	L5				
Italy (IT)	L6				
Spain (ES)	L3				
Switzerland (CH)	L2	🟨 345678901234505011		🟪 345678	

KIT 1 Assign
KIT 2 Assign
KIT 3 Assign

Material Catalogue (6) Auto-Create Material Add Remove

Material ID	Material Icon	Name
345678901234504711	🟥	Placebo EU
345678901234504712	🟩	Active 100mg EU
345678901234504713	🟦	Active 200mg EU
345678901234505011	🟨	Placebo US
345678901234505012	🟪	Active 100mg US
345678901234505013	🟪	Active 200mg US

Study Structure

| Treatment Group Definition | Treatment Schedule | Treatment Assignment |

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

Treatment Group ID	Treatment Group Description	Patient Ratio	Overage	Cohort	Shift	Shift Unit
TG04	Placebo (active 0mg double blind)	1				Day
TG03	Low dosage (active 100mg double blind)	1				Day
TG02	Medium dosage (active 200mg double blind)	1				Day
TG01	High dosage (active 400mg double blind)	1	10%			Day

Site Events

Draft saved Save Cancel

---

12. Assignment Overview

Medication Pack Types

| Pack Type Definition | Material Assignment | Assignment Overview |

Countries (9) Add Delete Search 🔍 ⚙

Country	Label Group	KIT1	KIT2	KIT3
Austria (AT)	L1	🟥 345678901234504711 Placebo EU	🟩 345678901234504712 Active 100mg EU	🟦 345678901234504713 Active 200mg EU
Canada (CA)	L7			
Germany (DE)	L1	🟥 345678901234504711 Placebo EU	🟩 345678901234504712 Active 100mg EU	🟦 345678901234504713 Active 200mg EU
France (FR)	L4			
United States (US)	L7			
India (IN)	L5			
Italy (IT)	L6			
Spain (ES)	L3			
Switzerland (CH)	L2	🟨 345678901234505011 Placebo US	🟪 345678901234505012 Active 100mg US	🟪 345678901234505013 Active 200mg US

Study Structure

| Treatment Group Definition | Treatment Schedule | Treatment Assignment |

Treatment Groups (4) Copy Add Delete Search 🔍 ⚙

Draft saved Save Cancel